Haemonetics Stock Rockets 49% With 11-Day Winning Streak
Haemonetics (HAE) stock hit day 11 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 49% return. The company has gained about $1.2 Bil in value over the last 11 days, with its current market capitalization at about $3.5 Bil. The stock remains 5.3% below its value at the end of 2024. This compares with year-to-date returns of 14.6% for the S&P 500.
Haemonetics recently extended its winning streak, fueled by a robust earnings beat and an upward revision to full-year guidance. Strong plasma share gains and disciplined cost management drove record operating margin expansion, while the completion of a significant share buyback program underscored robust capital allocation, igniting fresh analyst optimism and propelling the medical technology innovator higher.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There are a few things to fear in HAE stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (see Buy or Sell HAE). Nevertheless, asset allocation is a smarter path than stock picking. The asset allocation strategies of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. And now, Trefis High Quality Portfolio is part of it.
For quick background, HAE provides medical products and solutions, including automated plasma collection devices, blood component systems, disposables, and related software across plasma, blood center, and hospital segments.
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
Comparing HAE Stock Returns With The S&P 500
The following table summarizes the return for HAE stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | HAE | S&P 500 |
|---|---|---|
| 1D | 1.1% | -1.7% |
| 11D (Current Streak) | 49.5% | -2.2% |
| 1M (21D) | 52.1% | 1.0% |
| 3M (63D) | 37.5% | 4.5% |
| YTD 2025 | -5.3% | 14.6% |
| 2024 | -8.7% | 23.3% |
| 2023 | 8.7% | 24.2% |
| 2022 | 48.3% | -19.4% |
However, big gains can follow sharp reversals – but how has HAE behaved after prior drops? See HAE Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 62 S&P constituents with 3 days or more of consecutive gains and 40 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 28 |
| 4D | 8 | 12 |
| 5D | 15 | 0 |
| 6D | 6 | 0 |
| 7D or more | 6 | 0 |
| Total >=3 D | 62 | 40 |
Key Financials for Haemonetics (HAE)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $1.3 Bil | $1.4 Bil |
| Operating Income | $173.3 Mil | $201.2 Mil |
| Net Income | $117.6 Mil | $167.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2026 FQ1 | 2026 FQ2 |
|---|---|---|
| Revenues | $321.4 Mil | $327.3 Mil |
| Operating Income | $53.9 Mil | $67.1 Mil |
| Net Income | $34.0 Mil | $38.7 Mil |
While HAE stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.